

Ref: GLL/BSE/2022/Nov-08

Date: November 25, 2021

To  
Corporate Relations Manager  
BSE Limited  
Phiroje Jeejeebhoy Towers,  
Dalal Street,  
Mumbai – 400 001

To  
Listing Manager  
The Ahmedabad Stock Exchange Limited  
A-2, Kamdhenu Complex,  
Opposite Sahajanand College,  
120 Feet Ring Rd, Panjara Pol, Ambawadi,  
Ahmedabad – 380 015

To  
The Secretary  
The Calcutta Stock Exchange Limited  
#7, Lyons Range, Murgighata,  
Dalhousie, Kolkata – 700 001

**Sub:** Disclosure under Regulation.23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 of Gennex Laboratories Limited  
**Ref:** Script Code: 531739 & 890171/GENNEX

Dear Sir/Ma'am,

Pursuant to the provision of Regulation.23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the attached note on Related party Transaction on Consolidated basis for the Half Year ended September 30, 2022.

We request you to take note of the above information on record and acknowledge the receipt of the same.

Thanking you,

Yours Truly,

**For Gennex Laboratories Limited**

  
**Rajesh Vankadara**  
Company Secretary & Compliance Officer



**Encl:** As above

**Gennex Laboratories Limited**

**Disclosure on Related Party Transactions**  
**In pursuance with Regulation 23 (9) of SEBI (Listing Obligations and**  
**Disclosure Requirements) Regulations, 2015**

**GENNEX LABORATORIES LIMITED**

**List of related parties**

**a. Associates:**

1. Deccan Remedies Limited

**b. Joint Ventures: NIL**

**c. Subsidiary: NIL**

**d. Parent Company: NIL**

**e. Key managerial Persons:**

1. Mr. Arihant Baid – Managing Director
2. Mr. T M Gopalakrishnan – Whole-time Director
3. Mr. Laxmipat Baid – Chief Financial Officer
4. Mr. Rajesh Vankadara – Company Secretary

**f. Independent Directors:**

1. Mr. Y Ravinder Reddy
2. Ms. Sadhana Bhansali
3. Mr. A S Nageswar Rao



**g. Non-Executive Directors:**

1. Mr. Avasarala Ranga Rao Pantulu

**h. Entities in Which Directors Have Significant Influence**

1. Deccan Remedies Limited
2. Premier Fiscal Services Private Limited (Promoting Company)<sup>1</sup>

**For Gennex Laboratories Limited**


**Rajesh Vankadara**  
Company Secretary & Compliance Officer

---

<sup>1</sup> Mr. Arihant Baid holds 50% equity stake and Directorship in that Company.

**Gennex Laboratories Limited – Disclosure of Related Party Transactions for the second half-year ended on September 30, 2022(6 Months)**

											Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.							
Details of the party (listed entity/subsidiary entering into the transaction)		Details of the counter party						In case of Monies are due to either party as a result of the transaction (see Note 1)		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments					
#	Name	PAN	Name	PAN	Relationship of the Counterparty with the listed entity or its subsidiary	Type of Related Transaction (see Note 5)	Value of the Related party transactions as approved by the audit committee (see Note 6a)	Value of transaction during the reporting period (see Note 6b)	Opening Balance	Closing Balance	Nature of indebtedness loan/issuance of debt/any other etc.)	Cost (see Note 7)	Tenure	Nature loan/advance/inter-corporate deposit/investment)	Interest Rate (%)	Tenure	Secured/Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end-usage)
1	Gennex Laboratories Limited	AABCP3078M	Arihant Baid	AIQPB9606B	Chairman & Managing Director	Remuneration	As per policy approved by the Board, Audit Committee and Shareholders from time to time	1,514,400	0	0	-	-	-	-	-	-	-	
2	Gennex Laboratories Limited	AABCP3078M	Tiruvarur Muralidharan Gopalakrishnan	ACFPT4050J	Whole-time Director	Remuneration	As per policy approved by the Board, Audit Committee and Shareholders from time to time	1,221,306	0	0	-	-	-	-	-	-	-	
3	Gennex Laboratories Limited	AABCP3078M	Laxmipat Baid	ACZPB3522H	Chief Financial Officer	Remuneration	As per policy approved by the Board and Audit Committee from time to time	854,700	0	0	-	-	-	-	-	-	-	



**Gennex Laboratories Limited – Disclosure of Related Party Transactions for the second half-year ended on September 30, 2022(6 Months)**

4	Gennex Laboratories Limited	AABCP3078M	Rajesh Vankadara	AFZPV9668P	Company Secretary & Compliance Officer	Remuneration	As per policy approved by the Board and Audit Committee from time to time	508,800	0	0	-	-	-	-	-	-
5	Gennex Laboratories Limited	AABCP3078M	Yellu Ravinder Reddy	AAFYP9147D	Non-Executive Director (Independent)	Sitting Fees	Rs.2,500/- per Board and Committee Meeting	37,500	40,000	77,500	-	-	-	-	-	-
6	Gennex Laboratories Limited	AABCP3078M	Amudala Sreeramulu Nageswar Rao	ABYPN0836E	Non-Executive Director (Independent)	Sitting Fees	Rs.2,500/- per Board and Committee Meeting	50,000	25,000	25,000	-	-	-	-	-	-
7	Gennex Laboratories Limited	AABCP3078M	Sadhana Bhansali	BDEPB9927R	Non-Executive Director (Independent)	Sitting Fees	Rs.2,500/- per Board and Committee Meeting	10,000	22,500	32,500	-	-	-	-	-	-
8	Gennex Laboratories Limited	AABCP3078M	Avasarala Ranga Rao Pantulu	AIMPA1604Q	Non-Executive Director	Sitting Fees	Rs.2,500/- per Board and Committee Meeting	20,000	30,000	50,000	-	-	-	-	-	-
Total (of Note 6b)								4,216,706								

**Notes:**

- The details in this format are required to be provided for all transactions undertaken during the reporting period. However, opening and closing balances, including commitments, to be disclosed for existing related party transactions even if there is no new related party transaction during the reporting period.
- Where a transaction is undertaken between members of the consolidated entity (between the listed entity and its subsidiary or between subsidiaries), it may be reported once.
- Listed banks shall not be required to provide the disclosures with respect to related party transactions involving loans, inter-corporate deposits, advances or investments made or given by the listed banks.
- For companies with financial year ending March 31, this information has to be provided for six months ended September 30 and six months ended March 31. Companies with financial years ending in other months, the six months period shall apply accordingly.
- Each type of related party transaction (for e.g. sale of goods/services, purchase of goods/services or whether it involves a loan, inter-corporate deposit, advance or investment) with a single party shall be disclosed separately and there should be no clubbing or netting of transactions of same type. However, transactions with the same counterparty of the same type may be aggregated for the reporting period. For instance, sale transactions with the same party may be aggregated for the reporting period and purchase transactions may also be disclosed in a similar manner. There should be no netting off for sale and purchase transactions. Similarly, loans advanced to and received from the same counterparty should be disclosed separately, without any netting off.
- In case of a multi-year related party transaction:
  - The aggregate value of such related party transaction as approved by the audit committee shall be disclosed in the column "Value of the related party transaction as approved by the audit committee".
  - The value of the related party transaction undertaken in the reporting period shall be reported in the column "Value of related party transaction during the reporting period".
- "Cost" refers to the cost of borrowed funds for the listed entity.
- PAN will not be displayed on the website of the Stock Exchange(s).
- Transactions such as acceptance of fixed deposits by banks/NBFCs, undertaken with related parties, at the terms uniformly applicable / offered to all shareholders/ public shall also be reported.

